Product Name:	Anti-Human HLA-DR (MHC Class II) In Vivo Antibody - Ultra Low Endotoxin
Product Code:	IVMB0021
Size:	1mg, 5mg, 25mg, 50mg, 100mg
Clone:	L243
Protein:	HLA-DR
Product Type:	Monoclonal Antibody
Synonyms:	Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic
Isotype:	Mouse IgG2a
Reactivity:	Baboon, Chimpanzee, Cynomolgus Monkey, Marmoset, Rhesus Monkey, Squirrel Monkey, Canine, Human
Immunogen:	Unknown
Applications:	B, CyTOF®, Depletion, FC, IHC FF, IP, PhenoCycler®, WB
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥98% monomer by analytical SEC >95% by SDS Page
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Product Code	Product Name	Endotoxin Level
IVMB0020	Anti-Human HLA-DR (MHC Class II) In Vivo Antibody - Low Endotoxin	Low
IVMB0021	Anti-Human HLA-DR (MHC Class II) In Vivo Antibody - Ultra Low Endotoxin	Ultra Low

Applications:	B, CODEX®, CyTOF®, Depletion, FC, IHC FF, IP, WB
Recommended Usage:	FC The suggested concentration for this HLA-DR (Clone L243) antibody for staining cells in flow cytometry is ≤ 0.5 µg per 10⁶ in a volume of 100 µl or 100µl of whole blood. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this HLA-DR (Clone L243) antibody for use in western blotting is 1-10 µg/ml.
Reactivity:	Baboon, Chimpanzee, Cynomolgus Monkey, Marmoset, Rhesus Monkey, Squirrel Monkey, Canine, Human

Host Species:	Mouse
Specificity:	Clone L243 recognizes a conformational epitope on the human MHC class II molecule HLA-DRα, which depends on the correct folding of the αβ heterodimer1. It does not cross-react with HLA-DP or HLA-DQ.
Antigen Distribution:	HLA-DR is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
Immunogen:	Unknown
Concentration:	≥ 5.0 mg/ml
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥98% monomer by analytical SEC >95% by SDS Page
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

HLA-DR antibody, clone L243, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DR isotype (HLA-DR). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DR consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DRA and HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. HLA-DR expression is a marker of T cell activation and correlates with disease activity in patients with autoimmune disease8 and rapid progression in HIV infection9. Specific alleles of HLA-DR are associated with autoimmune diseases, including rheumatoid arthritis10.